blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3230471

EP3230471 - METHOD FOR PREDICTING RESPONSE TO BREAST CANCER THERAPEUTIC AGENTS AND METHOD OF TREATMENT OF BREAST CANCER [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  03.07.2020
Database last updated on 28.06.2024
FormerThe patent has been granted
Status updated on  26.07.2019
FormerGrant of patent is intended
Status updated on  05.03.2019
FormerExamination is in progress
Status updated on  19.02.2019
FormerGrant of patent is intended
Status updated on  15.10.2018
FormerExamination is in progress
Status updated on  30.03.2018
FormerRequest for examination was made
Status updated on  15.09.2017
FormerThe international publication has been made
Status updated on  09.01.2017
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
Medivation Prostate Therapeutics LLC
525 Market Street 36th Floor
San Francisco, CA 94105 / US
[2018/06]
Former [2017/42]For all designated states
Medivation Prostate Therapeutics, Inc.
525 Market Street
36th Floor
San Francisco, CA 94105 / US
Inventor(s)01 / PETERSON, Amy, Christian
6 Wellesley Drive
Lafayette, CA 94549 / US
02 / UPPAL, Hirdesh
1459 Allanmere Drive
San Ramon, CA 94582 / US
 [2017/42]
Representative(s)Gill Jennings & Every LLP
The Broadgate Tower
20 Primrose Street
London EC2A 2ES / GB
[2017/42]
Application number, filing date15831013.608.12.2015
[2017/42]
WO2015US64500
Priority number, dateUS201462091195P12.12.2014         Original published format: US 201462091195 P
US201562142504P03.04.2015         Original published format: US 201562142504 P
US201562167110P27.05.2015         Original published format: US 201562167110 P
[2017/42]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016094408
Date:16.06.2016
Language:EN
[2016/24]
Type: A1 Application with search report 
No.:EP3230471
Date:18.10.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 16.06.2016 takes the place of the publication of the European patent application.
[2017/42]
Type: B1 Patent specification 
No.:EP3230471
Date:28.08.2019
Language:EN
[2019/35]
Search report(s)International search report - published on:EP16.06.2016
ClassificationIPC:C12Q1/68, C12Q1/6886, A61K45/06, A61K31/337, A61K31/4166
[2018/43]
CPC:
C12Q1/6886 (EP,CN,KR,US); A61K31/337 (EP,KR,US); A61K31/4166 (EP,KR,US);
A61K45/00 (CN); A61K45/06 (KR,US); A61P15/14 (EP);
A61P35/00 (EP); A61P43/00 (EP); C12Q2600/106 (EP,CN,KR,US);
C12Q2600/112 (EP,CN,KR,US); C12Q2600/158 (EP,CN,KR,US) (-)
Former IPC [2017/42]C12Q1/68
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/42]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:VERFAHREN ZUR VORHERSAGE DER REAKTION AUF BRUSTKREBS-THERAPEUTIKA UND VERFAHREN ZUR BEHANDLUNG VON BRUSTKREBS[2017/42]
English:METHOD FOR PREDICTING RESPONSE TO BREAST CANCER THERAPEUTIC AGENTS AND METHOD OF TREATMENT OF BREAST CANCER[2017/42]
French:MÉTHODE DE PRÉDICTION D'UNE RÉPONSE À DES AGENTS DE TRAITEMENT DU CANCER DU SEIN ET MÉTHODE DE TRAITEMENT DU CANCER DU SEIN[2017/42]
Entry into regional phase28.06.2017National basic fee paid 
28.06.2017Designation fee(s) paid 
28.06.2017Examination fee paid 
Examination procedure28.06.2017Examination requested  [2017/42]
28.06.2017Date on which the examining division has become responsible
19.01.2018Amendment by applicant (claims and/or description)
04.04.2018Despatch of a communication from the examining division (Time limit: M04)
30.07.2018Reply to a communication from the examining division
16.10.2018Communication of intention to grant the patent
18.02.2019Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
06.03.2019Communication of intention to grant the patent
16.07.2019Fee for grant paid
16.07.2019Fee for publishing/printing paid
16.07.2019Receipt of the translation of the claim(s)
Divisional application(s)EP19192143.6  / EP3604556
Opposition(s)03.06.2020No opposition filed within time limit [2020/32]
Fees paidRenewal fee
03.10.2017Renewal fee patent year 03
31.12.2018Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU08.12.2015
AL28.08.2019
AT28.08.2019
CY28.08.2019
CZ28.08.2019
DK28.08.2019
EE28.08.2019
FI28.08.2019
HR28.08.2019
LT28.08.2019
LV28.08.2019
MC28.08.2019
MK28.08.2019
MT28.08.2019
NL28.08.2019
PL28.08.2019
RO28.08.2019
RS28.08.2019
SE28.08.2019
SI28.08.2019
SK28.08.2019
SM28.08.2019
TR28.08.2019
BG28.11.2019
NO28.11.2019
GR29.11.2019
LU08.12.2019
IS28.12.2019
PT30.12.2019
BE31.12.2019
CH31.12.2019
LI31.12.2019
[2022/32]
Former [2021/34]HU08.12.2015
AL28.08.2019
AT28.08.2019
CY28.08.2019
CZ28.08.2019
DK28.08.2019
EE28.08.2019
FI28.08.2019
HR28.08.2019
LT28.08.2019
LV28.08.2019
MC28.08.2019
MT28.08.2019
NL28.08.2019
PL28.08.2019
RO28.08.2019
RS28.08.2019
SE28.08.2019
SI28.08.2019
SK28.08.2019
SM28.08.2019
TR28.08.2019
BG28.11.2019
NO28.11.2019
GR29.11.2019
LU08.12.2019
IS28.12.2019
PT30.12.2019
BE31.12.2019
CH31.12.2019
LI31.12.2019
Former [2021/32]HU08.12.2015
AL28.08.2019
AT28.08.2019
CY28.08.2019
CZ28.08.2019
DK28.08.2019
EE28.08.2019
FI28.08.2019
HR28.08.2019
LT28.08.2019
LV28.08.2019
MC28.08.2019
NL28.08.2019
PL28.08.2019
RO28.08.2019
RS28.08.2019
SE28.08.2019
SI28.08.2019
SK28.08.2019
SM28.08.2019
TR28.08.2019
BG28.11.2019
NO28.11.2019
GR29.11.2019
LU08.12.2019
IS28.12.2019
PT30.12.2019
BE31.12.2019
CH31.12.2019
LI31.12.2019
Former [2021/26]AL28.08.2019
AT28.08.2019
CY28.08.2019
CZ28.08.2019
DK28.08.2019
EE28.08.2019
FI28.08.2019
HR28.08.2019
LT28.08.2019
LV28.08.2019
MC28.08.2019
NL28.08.2019
PL28.08.2019
RO28.08.2019
RS28.08.2019
SE28.08.2019
SI28.08.2019
SK28.08.2019
SM28.08.2019
TR28.08.2019
BG28.11.2019
NO28.11.2019
GR29.11.2019
LU08.12.2019
IS28.12.2019
PT30.12.2019
BE31.12.2019
CH31.12.2019
LI31.12.2019
Former [2020/51]AL28.08.2019
AT28.08.2019
CZ28.08.2019
DK28.08.2019
EE28.08.2019
FI28.08.2019
HR28.08.2019
LT28.08.2019
LV28.08.2019
MC28.08.2019
NL28.08.2019
PL28.08.2019
RO28.08.2019
RS28.08.2019
SE28.08.2019
SI28.08.2019
SK28.08.2019
SM28.08.2019
TR28.08.2019
BG28.11.2019
NO28.11.2019
GR29.11.2019
LU08.12.2019
IS28.12.2019
PT30.12.2019
BE31.12.2019
CH31.12.2019
LI31.12.2019
Former [2020/46]AL28.08.2019
AT28.08.2019
CZ28.08.2019
DK28.08.2019
EE28.08.2019
FI28.08.2019
HR28.08.2019
LT28.08.2019
LV28.08.2019
MC28.08.2019
NL28.08.2019
PL28.08.2019
RO28.08.2019
RS28.08.2019
SE28.08.2019
SI28.08.2019
SK28.08.2019
SM28.08.2019
TR28.08.2019
BG28.11.2019
NO28.11.2019
GR29.11.2019
LU08.12.2019
IS28.12.2019
PT30.12.2019
Former [2020/39]AL28.08.2019
AT28.08.2019
CZ28.08.2019
DK28.08.2019
EE28.08.2019
FI28.08.2019
HR28.08.2019
LT28.08.2019
LV28.08.2019
MC28.08.2019
NL28.08.2019
PL28.08.2019
RO28.08.2019
RS28.08.2019
SE28.08.2019
SI28.08.2019
SK28.08.2019
SM28.08.2019
TR28.08.2019
BG28.11.2019
NO28.11.2019
GR29.11.2019
IS28.12.2019
PT30.12.2019
Former [2020/37]AL28.08.2019
AT28.08.2019
CZ28.08.2019
DK28.08.2019
EE28.08.2019
FI28.08.2019
HR28.08.2019
LT28.08.2019
LV28.08.2019
NL28.08.2019
PL28.08.2019
RO28.08.2019
RS28.08.2019
SE28.08.2019
SI28.08.2019
SK28.08.2019
SM28.08.2019
TR28.08.2019
BG28.11.2019
NO28.11.2019
GR29.11.2019
IS28.12.2019
PT30.12.2019
Former [2020/36]AL28.08.2019
AT28.08.2019
CZ28.08.2019
DK28.08.2019
EE28.08.2019
FI28.08.2019
HR28.08.2019
LT28.08.2019
LV28.08.2019
NL28.08.2019
PL28.08.2019
RO28.08.2019
RS28.08.2019
SE28.08.2019
SK28.08.2019
SM28.08.2019
TR28.08.2019
BG28.11.2019
NO28.11.2019
GR29.11.2019
IS28.12.2019
PT30.12.2019
Former [2020/27]AL28.08.2019
AT28.08.2019
CZ28.08.2019
DK28.08.2019
EE28.08.2019
FI28.08.2019
HR28.08.2019
LT28.08.2019
LV28.08.2019
NL28.08.2019
PL28.08.2019
RO28.08.2019
RS28.08.2019
SE28.08.2019
SK28.08.2019
SM28.08.2019
TR28.08.2019
BG28.11.2019
NO28.11.2019
GR29.11.2019
PT30.12.2019
IS24.02.2020
Former [2020/25]AL28.08.2019
AT28.08.2019
CZ28.08.2019
DK28.08.2019
EE28.08.2019
FI28.08.2019
HR28.08.2019
LT28.08.2019
LV28.08.2019
NL28.08.2019
PL28.08.2019
RO28.08.2019
RS28.08.2019
SE28.08.2019
SK28.08.2019
TR28.08.2019
BG28.11.2019
NO28.11.2019
GR29.11.2019
PT30.12.2019
IS24.02.2020
Former [2020/24]AL28.08.2019
AT28.08.2019
DK28.08.2019
EE28.08.2019
FI28.08.2019
HR28.08.2019
LT28.08.2019
LV28.08.2019
NL28.08.2019
PL28.08.2019
RO28.08.2019
RS28.08.2019
SE28.08.2019
TR28.08.2019
BG28.11.2019
NO28.11.2019
GR29.11.2019
PT30.12.2019
IS24.02.2020
Former [2020/23]AL28.08.2019
AT28.08.2019
DK28.08.2019
EE28.08.2019
FI28.08.2019
HR28.08.2019
LT28.08.2019
LV28.08.2019
NL28.08.2019
PL28.08.2019
RO28.08.2019
RS28.08.2019
SE28.08.2019
TR28.08.2019
BG28.11.2019
NO28.11.2019
GR29.11.2019
IS28.12.2019
PT30.12.2019
Former [2020/22]AL28.08.2019
DK28.08.2019
EE28.08.2019
FI28.08.2019
HR28.08.2019
LT28.08.2019
LV28.08.2019
NL28.08.2019
RS28.08.2019
SE28.08.2019
TR28.08.2019
BG28.11.2019
NO28.11.2019
GR29.11.2019
IS28.12.2019
PT30.12.2019
Former [2020/17]AL28.08.2019
FI28.08.2019
HR28.08.2019
LT28.08.2019
LV28.08.2019
NL28.08.2019
RS28.08.2019
SE28.08.2019
TR28.08.2019
BG28.11.2019
NO28.11.2019
GR29.11.2019
IS28.12.2019
PT30.12.2019
Former [2020/15]AL28.08.2019
FI28.08.2019
HR28.08.2019
LT28.08.2019
LV28.08.2019
NL28.08.2019
RS28.08.2019
SE28.08.2019
BG28.11.2019
NO28.11.2019
GR29.11.2019
IS28.12.2019
PT30.12.2019
Former [2020/12]FI28.08.2019
HR28.08.2019
LT28.08.2019
LV28.08.2019
NL28.08.2019
RS28.08.2019
SE28.08.2019
BG28.11.2019
NO28.11.2019
GR29.11.2019
IS28.12.2019
PT30.12.2019
Former [2020/10]FI28.08.2019
LT28.08.2019
NL28.08.2019
SE28.08.2019
BG28.11.2019
NO28.11.2019
PT30.12.2019
Former [2020/09]FI28.08.2019
LT28.08.2019
NL28.08.2019
NO28.11.2019
Former [2020/08]LT28.08.2019
NO28.11.2019
Cited inInternational search[I]WO2013066440  (MEDIVATION PROSTATE THERAPEUTICS INC [US], et al) [I] 37 * Whole document, especially claim 42 *;
 [XY]  - Traina T A et al, "Stage Stage 1 results from MDV3100-11: A 2-stage study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, inadvanced AR+ triple-negative breast cancer (TNBC)", 2014 San Antonio Breast Cancer Symposium, Database accession no. P5-19-09, page 1130, SABCS, URL: https://www.sabcs.org/Portals/SABCS2016/Documents/2014SABCSCall4Abstracts.pdf, XP002755850 [X] 37 * page 1130 * [Y] 1-36,38-80
 [Y]  - IVANA MRKLIC ET AL, "Expression of androgen receptors in triple negative breast carcinomas", ACTA HISTOCHEMICA, AMSTERDAM, NL, (20130501), vol. 115, no. 4, doi:10.1016/j.acthis.2012.09.006, ISSN 0065-1281, pages 344 - 348, XP055261018 [Y] 1-36,38-80 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.acthis.2012.09.006
 [I]  - F. M. FIORETTI ET AL, "Revising the role of the androgen receptor in breast cancer", JOURNAL OF MOLECULAR ENDOCRINOLOGY., GB, (20140527), vol. 52, no. 3, doi:10.1530/JME-14-0030, ISSN 0952-5041, pages R257 - R265, XP055260941 [I] 37 * Whole document, especially page 262, left column, second full paragraph and continuing. *

DOI:   http://dx.doi.org/10.1530/JME-14-0030
 [I]  - Garth Sundem, "Study Shows Anti-Androgen Receptor Therapy for Triple-Negative Breast Cancer May Benefit More Than Just High-Androgen Receptor Tumors - Colorado Cancer Blogs", (20140623), URL: http://www.coloradocancerblogs.org/study-shows-anti-androgen-receptor-therapy-triple-negative-breast-cancer-may-benefit-just-high-androgen-receptor-tumors/, (20160324), XP055260955 [I] 37 * the whole document *
 [A]  - THIKE AYE AYE ET AL, "Loss of androgen receptor expression predicts early recurrence in triple-negative and basal-like breast cancer", MODERN PATHOLOGY, (201403), vol. 27, no. 3, ISSN 0893-3952, pages 352 - 360, XP002755895 [A] 1-80 * abstract *

DOI:   http://dx.doi.org/10.1038/modpathol.2013.145
 [A]  - FRANÇOIS BERTUCCI ET AL, "How basal are triple-negative breast cancers?", INTERNATIONAL JOURNAL OF CANCER, US, (20080701), vol. 123, no. 1, doi:10.1002/ijc.23518, ISSN 0020-7136, pages 236 - 240, XP055260796 [A] 1-80 * abstract *

DOI:   http://dx.doi.org/10.1002/ijc.23518
 [AD]  - PARKER JOEL S ET AL, "Supervised risk predictor of breast cancer based on intrinsic subtypes", JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, (20090310), vol. 27, no. 8, doi:10.1200/JCO.2008.18.1370, ISSN 0732-183X, pages 1160 - 1167, XP009124878 [AD] 1-80 * the whole document *

DOI:   http://dx.doi.org/10.1200/JCO.2008.18.1370
 [A]  - M. C.U. CHEANG ET AL, "Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype", CLINICAL CANCER RESEARCH, US, (20080301), vol. 14, no. 5, doi:10.1158/1078-0432.CCR-07-1658, ISSN 1078-0432, pages 1368 - 1376, XP055260805 [A] 1-80 * abstract *

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-07-1658
 [A]  - DAWN R COCHRANE ET AL, "Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide", BREAST CANCER RESEARCH, CURRENT SCIENCE, LONDON, GB, (20140122), vol. 16, no. 1, doi:10.1186/BCR3599, ISSN 1465-5411, pages 1 - 19, XP021177323 [A] 1-80 * the whole document *

DOI:   http://dx.doi.org/10.1186/bcr3599
 [AD]  - CHOO JENNIFER R ET AL, "Biomarkers for Basal-like Breast Cancer.", CANCERS 2010, (2010), vol. 2, no. 2, ISSN 2072-6694, pages 1040 - 1065, XP002755894 [AD] 1-80 * the whole document *

DOI:   http://dx.doi.org/10.3390/cancers2021040
ExaminationWO2012125828
by applicantUS4683202
 US5800992
 US6020135
 US6033860
 US6040138
 US6344316
 US2009299640
 US2011145176
 US2013004482
    - PEROU ET AL., NATURE, (2000), vol. 406, no. 6797, pages 747 - 52
    - SORLIE ET AL., PNAS, (2001), vol. 98, no. 19, pages 10869 - 74
    - COLLINS ET AL., MOD PATHOL, (2011), vol. 24, no. 7, pages 924 - 931
    - GARAY; PARK, AM. J CANCER RES., (2012), vol. 2, no. 4, pages 434 - 445
    - OGAWA ET AL., INT J CLIN, ONCOL., (2008), vol. 13, page 431435
    - BERTUCCI ET AL., INT. J CANCER, (2008), vol. 123, pages 236 - 240
    - WANG ET AL., EUR. J CLIN. INVEST., (2008), vol. 38, pages 438 - 446
    - CHOO; NIELSEN, CANCERS, (2010), vol. 2, pages 1040 - 1065
    - NIELSEN ET AL., CLINICAL CANCER RESEARCH, (2014), vol. 10, pages 5367 - 5374
    - PEROU ET AL., NATURE, (2000), vol. 406, pages 747 - 752
    - PARKER ET AL., J CLIN ONEAL., (2009), vol. 27, no. 8, pages 1160 - 7
    - PARKER ET AL., J CLIN. ONCOL., (2009), vol. 27, no. 8, pages 1160 - 7
    - PRAT ET AL., BRITISH JOURNAL OF CANCER, (2014), vol. 111, pages 1532 - 1541
    - WEIS ET AL., TIG, (1992), vol. 8, pages 263 - 64
    - SCHENA ET AL., SCIENCE, (1995), vol. 270, pages 467 - 70
    - RUPP; LOCKER, LAB INVEST., (1987), vol. 56, page A67
    - DE ANDRES ET AL., BIOTECHNIQUES, (1995), vol. 18, pages 42 - 44
    - QUACKENBUSH, NAT. GENET., (2002), vol. 32, pages 496 - 501
    - NUCLEIC ACIDS RES., (201010), vol. 38, no. 18, page E178
    - "Comprehensive Molecular Portraits of Human Breast Tumors", NATURE, vol. 490, (20121004), pages 61 - 70, URL: http://www.nature.com/nature/iournal/v490/n7418/fu l/naturel 1412.html
    - PARKER ET AL., J CLIN ONCOL., (2009), vol. 27, no. 8, pages 1160 - 7
    - NUCLEIC ACIDS RES., (201010), vol. 38, no. 18, page EL78
    - "Comprehensive Molecular Portraits of Human Breast Tumors", NATURE, vol. 490, (20121004), pages 61 - 70, URL: http://www.nature.com/nature/journal/v490/n7418/full/nature 11412.html
    - AYCA ET AL., "Phase II Trial of Bicalutamide in Patients with Androgen Receptor Positive, Hormone Receptor Negative Metastatic Breast Cancer", CLIN CANCER RES, (20131001), vol. 19, pages 5505 - 5512
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.